

To: Office of the Vermont Attorney General
AGO.highcostprescriptiondrugs@vermont.gov

From: Sandoz Inc.
100 College Road West
Princeton, NJ 08540

Date: August 13, 2021

Re: Vermont Act 193 (18 V.S.A. §4637)

On July 16, 2021, Sandoz Inc. ("Sandoz") notified the Office of the Vermont Attorney General ("Attorney General") of a new prescription drug, ferumoxytol, pursuant to 18 V.S.A §4637(b).

NDC	Drug Product Description	Introduced to Market Date	WAC at Introduction
00781-3154-01	FERUMOXYTOL INJ 510MG/17ML 1LIVI	7/15/2021	\$869.14

Sandoz hereby notifies the Attorney General of the additional information required, pursuant to 18 V.S.A §4637(c).

Statutory Requirement	Reporting Information
A description of the marketing and pricing plans used in the launch of the new drug in the United States and internationally	This launch is specific to the U.S. Sandoz Inc. is contracting within the oncology and hospital space. Resources are available for hospital buyers. The WAC is priced lower than the WAC of the reference product.
The estimated volume of patients who may be prescribed the drug	According to the National Heart, Lung, and Blood Institute, an estimated 3 million individuals suffer from anemia in the U.S. Increasing prevalence of target diseases, such as rheumatoid arthritis, autoimmune diseases, kidney conditions, cancer, liver disorders, thyroid diseases, and inflammatory bowel diseases, is a major factor facilitating the growth of the market for intravenous iron drugs. Some of the most common forms of anemia are iron and vitamin deficiency, a plastic, hemolytic, and sickle cell. Some of the common causes of anemia are iron, vitamin A and B12, and folate deficiencies. Source: https://www.grandviewresearch.com/industry-analysis/intravenous-iron-drugs-market
Whether the drug was granted breakthrough therapy designation or priority review by the FDA prior to final approval	N/A
The date and price of acquisition if the drug was not developed by the manufacturer	N/A

Sandoz Inc. provides this report consistent with its understanding and interpretation of Vermont Act 193 (18 V.S.A. § 4637) and its provisions. In providing this report, Sandoz Inc. does not waive any rights that may have at law or in equity with respect to the applicability, interpretation, or application of Vermont Act 193 (18 V.S.A. § 4637) as it may relate to Sandoz Inc. or any of its affiliates now or in the future. Sandoz Inc., on behalf of itself and affiliates, expressly reserves all such rights. We believe that all information submitted by Sandoz Inc. to the Department of Vermont Health Access or to the Attorney General under Vt. Stat. tit. 18 §§ 4635 or 4637, including all information contained in this submission, is confidential and proprietary commercial or financial information not subject to disclosure, including under the Vermont Public Records Act (Subchapter 3 of Chapter 5 of the Vermont Statutes) and applicable laws pertaining to trade secrets. We request that your company or organization maintain the confidentiality of this submission and of all Sandoz Inc.'s related information herein to the maximum extent permitted by law. To the extent that any of this designated information is requested, whether under Vermont Public Records Act (Subchapter 3 of Chapter 5 of the Vermont Statutes) or otherwise, we request that your company or organization notify us of the request and afford us the opportunity to submit objections to disclosure.

For any questions concerning this notification, please contact:
state.transparency@sandoz.com.